MaaT Pharma SA (EPA:MAAT)

Market Cap	85.27M
Revenue (ttm)	3.22M
Net Income (ttm)	-28.90M
Shares Out	13.98M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,833
Average Volume	6,881
Open	6.38
Previous Close	6.32
Day's Range	6.00 - 6.54
52-Week Range	5.66 - 9.96
Beta	0.13
RSI	46.64
Earnings Date	Mar 26, 2025

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 60
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.